The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (108)
May 18, 2009
-
Maurer's Healthcare Insight (107)
April 27, 2009
-
Maurer's Healthcare Insight (106)
March 30, 2009
-
Maurer's Healthcare Insight (105)
March 2, 2009
-
Maurer's Healthcare Insight (104)
January 26, 2009
-
Maurer's Healthcare Insight (103)
January 5, 2009
-
Maurer's Healthcare Insight (102)
December 8, 2008
-
Maurer's Healthcare Insight (101)
December 1, 2008
-
Maurer's Healthcare Insight (100)
October 27, 2008
-
Maurer's Healthcare Insight (99)
September 29, 2008
-
Maurer's Healthcare Insight (98)
August 25, 2008
-
Maurer's Healthcare Insight (97)
July 28, 2008
-
Maurer's Healthcare Insight (96)
June 23, 2008
-
Maurer's Healthcare Insight (95)
May 19, 2008
-
Maurer's Healthcare Insight (94)
March 10, 2008
-
Maurer's Healthcare Insight (93)
February 18, 2008
-
Maurer's Healthcare Insight (92)
January 21, 2008
-
Maurer's Healthcare Insight (91)
December 24, 2007
-
Maurer's Healthcare Insight (90)
November 5, 2007
-
Maurer's Healthcare Insight (89)
October 8, 2007
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…